)
CSPC Pharmaceutical Group (1093) investor relations material
CSPC Pharmaceutical Group Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
9M 2026 revenue rose 27.0% YoY to RMB25,260M, including RMB6,268M of licence-fee income; reported profit attributable to shareholders increased 101.5% to RMB7,076M.
Q3 revenue rose 0.7% YoY to RMB6,665M; finished-drug revenue excluding BD income grew 10.1% to RMB5,215M.
Gross profit increased 27.0% to RMB18,598M and gross margin rose 8.0pp to 73.6%.
Financial highlights
9M underlying profit, excluding FVTPL fair-value changes and share-based compensation, increased 134.5% to RMB7,220M; basic and diluted EPS were RMB62.14 and RMB61.99 cents, up 102.3% and 101.8%.
Profit before tax was RMB8,756M versus RMB4,303M; profit for the period was RMB7,446M versus RMB3,536M.
9M R&D expenses rose 10.9% to RMB4,643M, equal to 24.4% of revenue excluding BD income; selling expenses were RMB4,919M, or 25.9% on that basis.
Q3 reported profit attributable to shareholders rose 1.9% to RMB982M; R&D expenses increased 7.4% to RMB1,614M, while selling expenses fell 6.9% to RMB1,628M.
Segment performance
Finished-drug revenue rose 40.1% to RMB21,648M, including RMB6,268M in licence fees; product sales excluding licence fees grew 10.6%.
Nervous-system finished-drug sales increased 29.1% to RMB7,318M; digestion and metabolism sales rose 14.2% to RMB887M.
Bulk products revenue fell 22.3% to RMB2,336M; Vitamin C sales declined 18.9% to RMB1,451M and antibiotics fell 27.3% to RMB885M.
Functional food and other revenue decreased 11.1% to RMB1,276M, reflecting lower sales volume and prices for anhydrous glucose and caffeine.
- Finished-drug growth lifted revenue, but weaker bulk-product pricing pressured margins.1093
H2 2023 - Revenue and profit soared on finished drug sales and major licensing deals with AstraZeneca.1093
Q2 2026 - Revenue and profit fell sharply, but R&D and licensing activity remain strong.1093
Q1 2026 - Revenue fell 10.4% YoY, but licensing, R&D, and global expansion fueled future growth.1093
H2 2025 - Revenue and profit fell amid policy headwinds, but R&D and global deals fueled future growth.1093
Q3 2025 - Revenue and profit fell on procurement pressures, but innovation and global deals drive future growth.1093
H1 2025 - Revenue and profit fell, but R&D, new drugs, and licensing deals drive future growth.1093
Q3 2024 - Modest profit growth, strong R&D, and higher shareholder returns amid mixed segment trends.1093
H1 2024 - Revenue and profit fell, but R&D and global licensing deals support future growth.1093
Q1 2025
)
)
)
)
)
)
)
)